The Latest Psychedelics Articles from Streetwise Reports

Healthcare Co.'s New Protocol 3.5X More Efficient Addiction Treatment

  ()
This U.K. healthcare company revealed a compound that's 3.5x more effective in treating alcohol use disorder than the industry standard. Now, expansion is on the horizon.

Potential ROI With German Biopharma Co. Notable

Research Report
  ()
This firm, with eight treatment candidates for mental health disorders in development, boasts a catalyst-rich next two months, noted a ROTH Capital Partners report.

Biopharma Target Price 10 Times Current

Research Report
  ()
Read to learn why ROTH Capital Partners gave Atai Life Sciences NV a Buy rating and a target price 10 times its current.
Tags:  Psychedelics

Opportunity for Investors Found in Psychedelics Space

Research Report
  ()
Treatment of alcohol use disorder with psychedelics plus therapy is effective, according to existing data, and the potential global market is large, noted an H.C. Wainwright & Co. report.
Tags:  Psychedelics

Biotech Co.'s Target Six Times Current Price

Research Report
  ()
One Phase 2 clinical trial showing LSD reduced symptoms of anxiety bodes well for other studies of LSD in this indication. In light of this, Oppenheimer & Co. gave this biotech company a target price that is over six times its current share price.
Tags:  Psychedelics

Healthcare Co.'s To Develop Fast-Dissolving MDMA Tablet

  ()
One biopharma co. is teaming with a much larger pharmaceutical company to develop a fast-dissolving oral tablet to deliver MDMA to patients with Alcohol Use Disorder. Find out why developing an oral tablet could benefit the company in the long run.

Expert Says Life Science Corp.'s Technical Case Is Becoming Compelling

Contributed Opinion
  ()
Expert Clive Maund shares his view on Awakn Life Sciences Corp. as its stock continues to strengthen.

Healthcare Co. Wants Share of $17.5B Addiction Treatment Industry

Research Report
  ()
One healthcare co. is currently rated a Buy and is making a push for a share of the $17.5-billion addiction treatment industry after a recent study showed its psychedelic-assisted psychotherapy treatment showed a significant decrease in alcohol use, noted a Maxim Group equity research report.

Analyst Sees 'Attractive Long-Term Economics' for Healthcare Co.

Research Report
  ()
One healthcare company with upcoming catalysts wants to take a share of the CA$6-billion alcoholism treatment market with its proprietary psychedelic-assisted psychotherapy treatments.

Drug Co. to Conduct P1/2a Trial of Psilocybin in Depression

Research Report
  ()
In this trial, slated to commence next quarter, the biopharma will test the efficacy of its version of the psychedelic compound in this mental health indication, noted a ROTH Capital Partners report.
Tags:  Psychedelics

Showing Results: 1 to 10 of 10